8-K: Owlet Announces CFO Transition, Appoints Amanda Twede Crawford, Reaffirms 2024 Financial Goals

Owlet, Inc. has announced a CFO transition, with Amanda Twede Crawford succeeding Kate Scolnick, and reaffirmed its 2024 financial goals.

Summary

• Owlet, Inc. has appointed Amanda Twede Crawford as the new Chief Financial Officer, effective July 9, 2024, succeeding Kate Scolnick.
• Kate Scolnick will remain with the company in an advisory role until September 6, 2024, to ensure a smooth transition.
• Amanda Twede Crawford previously served as Vice President, Financial Planning and Analysis at Owlet since March 2022.
• Ms. Crawford's new annual base salary is $300,000, with a potential annual cash bonus of 35% of her base salary.
• She is also eligible for an equity award with a target value between $200,000 and $300,000 in restricted stock units.
• Kate Scolnick will receive six months of her base salary and target bonus, COBRA premium reimbursement, accelerated vesting of unvested stock options and restricted stock units, and outplacement services as part of her separation agreement.
• Owlet has reaffirmed its 2024 financial goals and is on track to achieve its operational and financial objectives.
• The company is seeing strong growth outside of the US market, particularly in the EU and UK.
• Owlet is also expanding its presence in the remote patient monitoring segment.
• The company is progressing towards its goal of reaching and maintaining Adjusted EBITDA breakeven.
• Owlet will release its second quarter 2024 financial results on August 12, 2024.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the reaffirmation of financial goals, strong international growth, and the smooth CFO transition. However, the company is still working towards profitability, and there are inherent risks in the business.

Positives

• The appointment of Amanda Twede Crawford as CFO is a positive step, given her experience and prior role within the company.
• The company is on track to achieve its 2024 operational and financial goals.
• Owlet is experiencing strong growth in international markets, particularly in the EU and UK.
• The company is expanding its presence in the remote patient monitoring segment.
• Owlet is making progress towards its goal of reaching and maintaining Adjusted EBITDA breakeven.
• The transition plan for the CFO role includes an advisory period for the outgoing CFO, ensuring a smooth handover.

Negatives

• The departure of the current CFO, Kate Scolnick, may create some uncertainty, although a transition plan is in place.
• The company is still working towards achieving Adjusted EBITDA breakeven, indicating that profitability is not yet fully secured.

Risks

• The company's future results may differ materially from forward-looking statements due to various factors.
• Regulatory pathways for Owlet's products, including FDA approvals, pose a risk.
• Competition and the company's ability to manage growth are ongoing risks.
• The company's ability to obtain additional financing and manage debt is a risk.
• The company's ability to implement strategic initiatives and adapt to changes in consumer preferences is a risk.
• The company faces risks related to intellectual property, data protection, and maintaining relationships with customers and suppliers.
• Economic conditions, health epidemics, and other external factors could disrupt the business.
• Changes in consumer spending and preferences could adversely affect the company.

Future Outlook

Owlet is focused on executing its strategic operational goals for the remainder of 2024 and beyond, with a focus on international growth, expansion in remote patient monitoring, and achieving Adjusted EBITDA breakeven. The company will release its second quarter 2024 financial results on August 12, 2024.

Management Comments

• Kurt Workman, Owlet CEO, thanked Kate Scolnick for her contributions and stated she was instrumental in supporting top line growth, margin expansion and profitability objectives.
• Kurt Workman stated that with Kate's help, Owlet is on track to achieve its 2024 operational and financial goals.
• Kurt Workman expressed excitement for Amanda Twede Crawford moving into the CFO role and anticipates a smooth transition.
• Kurt Workman highlighted Owlet's strong momentum and business performance in 2024.
• Kurt Workman noted the company's strong inroads outside of the core US market, especially in the EU and UK.
• Kurt Workman stated that Owlet is expanding its presence in the large remote patient monitoring segment.
• Kurt Workman mentioned that the company is progressing towards its stated goal of reaching and maintaining Adjusted EBITDA breakeven.

Industry Context

The announcement reflects a common trend in the tech and healthcare sectors where companies are focusing on growth and profitability. The emphasis on international expansion and remote patient monitoring aligns with broader industry trends in digital health and telehealth. The CFO transition is a normal part of corporate evolution, and the company's focus on achieving EBITDA breakeven is a key indicator of its maturity and financial discipline.

Comparison to Industry Standards

• The CFO transition at Owlet is similar to executive changes seen in other growth-stage companies, such as those in the digital health space like Teladoc Health or Livongo (now part of Teladoc).
• The focus on international expansion mirrors strategies of companies like Masimo and Philips, which have a global presence in medical devices and monitoring.
• The goal of achieving Adjusted EBITDA breakeven is a common benchmark for companies in the healthcare technology sector, similar to companies like Dexcom and Insulet.
• The emphasis on remote patient monitoring aligns with the trend of increased adoption of telehealth solutions, as seen with companies like Omada Health and BioTelemetry.
• The financial metrics for the new CFO's compensation are within the typical range for similar roles in comparable companies.

Management Changes

Stakeholder Impact

• Shareholders will be interested in the company's progress towards profitability and the reaffirmed financial goals.
• Employees may experience some change with the CFO transition, but the company is aiming for a smooth handover.
• Customers should not be directly impacted by the CFO transition, but may benefit from the company's continued growth and product development.
• Suppliers and creditors will be interested in the company's financial stability and growth prospects.

Next Steps

• Owlet will release its second quarter 2024 financial results on August 12, 2024.
• The company will host a conference call on August 12, 2024, to discuss the results and provide a business update.

Key Dates

Keywords

CFO, Chief Financial Officer, financial goals, financial results, EBITDA, remote patient monitoring, international growth, executive transition, FDA, financial planning, accounting